These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 9702435)

  • 1. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.
    Hollander PA; Elbein SC; Hirsch IB; Kelley D; McGill J; Taylor T; Weiss SR; Crockett SE; Kaplan RA; Comstock J; Lucas CP; Lodewick PA; Canovatchel W; Chung J; Hauptman J
    Diabetes Care; 1998 Aug; 21(8):1288-94. PubMed ID: 9702435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial.
    Kelley DE; Bray GA; Pi-Sunyer FX; Klein S; Hill J; Miles J; Hollander P
    Diabetes Care; 2002 Jun; 25(6):1033-41. PubMed ID: 12032111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.
    Miles JM; Leiter L; Hollander P; Wadden T; Anderson JW; Doyle M; Foreyt J; Aronne L; Klein S
    Diabetes Care; 2002 Jul; 25(7):1123-8. PubMed ID: 12087008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor.
    Finer N; James WP; Kopelman PG; Lean ME; Williams G
    Int J Obes Relat Metab Disord; 2000 Mar; 24(3):306-13. PubMed ID: 10757623
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial.
    Hanefeld M; Sachse G
    Diabetes Obes Metab; 2002 Nov; 4(6):415-23. PubMed ID: 12406041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group.
    Sjöström L; Rissanen A; Andersen T; Boldrin M; Golay A; Koppeschaar HP; Krempf M
    Lancet; 1998 Jul; 352(9123):167-72. PubMed ID: 9683204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
    Muls E; Kolanowski J; Scheen A; Van Gaal L;
    Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
    Jacob S; Rabbia M; Meier MK; Hauptman J
    Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin.
    Berne C;
    Diabet Med; 2005 May; 22(5):612-8. PubMed ID: 15842517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with orlistat reduces cardiovascular risk in obese patients.
    Zavoral JH
    J Hypertens; 1998 Dec; 16(12 Pt 2):2013-7. PubMed ID: 9886891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial.
    Chanoine JP; Hampl S; Jensen C; Boldrin M; Hauptman J
    JAMA; 2005 Jun; 293(23):2873-83. PubMed ID: 15956632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial.
    Davidson MH; Hauptman J; DiGirolamo M; Foreyt JP; Halsted CH; Heber D; Heimburger DC; Lucas CP; Robbins DC; Chung J; Heymsfield SB
    JAMA; 1999 Jan; 281(3):235-42. PubMed ID: 9918478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A one-year trial to assess the value of orlistat in the management of obesity.
    James WP; Avenell A; Broom J; Whitehead J
    Int J Obes Relat Metab Disord; 1997 Jun; 21 Suppl 3():S24-30. PubMed ID: 9225173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia.
    Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z
    Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group.
    Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G
    Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients.
    Derosa G; Maffioli P; Ferrari I; D'Angelo A; Fogari E; Palumbo I; Randazzo S; Cicero AF
    Fundam Clin Pharmacol; 2011 Oct; 25(5):642-51. PubMed ID: 21077943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.
    Shi YF; Pan CY; Hill J; Gao Y
    Diabet Med; 2005 Dec; 22(12):1737-43. PubMed ID: 16401321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes.
    Kelley DE; Kuller LH; McKolanis TM; Harper P; Mancino J; Kalhan S
    Diabetes Care; 2004 Jan; 27(1):33-40. PubMed ID: 14693963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.